The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

The partners are advancing a pipeline of engineered DNase I therapies designed to work with CAR T cells to kill tumor cells.

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.

NEW YORK – The Children's Hospital of Philadelphia (CHOP) on Thursday announced a partnership with the Brazilian National Cancer Institute (INCA) to expand access to CAR T-cell therapies among ...

A half-dozen hospital systems plan to implement the tool, which combs through patient medical records to identify those ...

The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.

NEW YORK – Cel-Sci on Thursday said the US Food and Drug Administration agreed with its plan to select head and neck cancer patients with low PD-L1 tumor expression in a confirmatory registrational ...

Relevant genes to test for hereditary prostate cancer include ATM, BRCA1, BRCA2, CHEK2, HOXB13, and TP53, according to the guidelines. For all four cancer types included in these guidelines, NCCN also ...

SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations amenable to exon 51 skipping. With this ...

The funding will allow CUH to buy new equipment for administering treatments such as CAR T-cell therapies, reducing patients' need to travel long distances.

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.